Anticoagulation in Patients With Venous Thromboembolism and Cancer
NCT04618913
Last updated date
ABOUT THIS STUDY
This study is a retrospective analysis of observational cohorts using data from prospectively
collected administrative/claims data to investigate treatment patterns,healthcare resource
utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness
outcomes in patients with VTE and active cancer or patients with VTE and history of cancer
who initiate anticoagulant treatment with a VKA, LMWH or NOACs.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms, Embolism
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- A VTE diagnosis
- Active cancer or history of cancer
- Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
- Age ≥ 18 years at the date of index VTE (Venous thromboembolic)
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Prior VTE diagnosis
- Diagnosis of prior atrial fibrillation
- Inferior Vena Cava (IVC) filter
- Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation -
note: Prophylactic use of (OAC)/(PAC) allowed.
- Pregnancy
- More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed
on the index date.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Neoplasms, EmbolismAnticoagulation in Patients With Venous Thromboembolism and Cancer
NCT04618913
- London,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||||
|---|---|---|---|---|---|---|---|
| Brief Title | Anticoagulation in Patients With Venous Thromboembolism and Cancer | ||||||
| Official Title | VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe) | ||||||
| Brief Summary | This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs. | ||||||
| Detailed Description | Not Provided | ||||||
| Study Type | Observational | ||||||
| Study Design | Observational Model: Cohort Time Perspective: Retrospective | ||||||
| Target Follow-Up Duration | Not Provided | ||||||
| Biospecimen | Not Provided | ||||||
| Sampling Method | Non-Probability Sample | ||||||
| Study Population | Adult patients with a diagnosis of (VTE) venous thromboembolism and active cancer, or a history of cancer, being treated with anticoagulation. | ||||||
| Condition |
| ||||||
| Intervention |
| ||||||
| Study Groups/Cohorts |
| ||||||
| Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
| Recruitment Information | |||||||
| Recruitment Status | Active, not recruiting | ||||||
| Actual Enrollment | 1 | ||||||
| Original Estimated Enrollment | Same as current | ||||||
| Estimated Study Completion Date | September 30, 2021 | ||||||
| Estimated Primary Completion Date | September 30, 2021 (Final data collection date for primary outcome measure) | ||||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||||
| Sex/Gender |
| ||||||
| Ages | Child, Adult, Older Adult | ||||||
| Accepts Healthy Volunteers | No | ||||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||||
| Listed Location Countries | United Kingdom | ||||||
| Removed Location Countries | |||||||
| Administrative Information | |||||||
| NCT Number | NCT04618913 | ||||||
| Other Study ID Numbers | B0661150 | ||||||
| Has Data Monitoring Committee | No | ||||||
| U.S. FDA-regulated Product |
| ||||||
| IPD Sharing Statement |
| ||||||
| Responsible Party | Pfizer | ||||||
| Study Sponsor | Pfizer | ||||||
| Collaborators | Not Provided | ||||||
| Investigators |
| ||||||
| PRS Account | Pfizer | ||||||
| Verification Date | February 2021 | ||||||